Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis

Fokkens, Wytske J., Mullol, Joaquim, Kennedy, David, Philpott, Carl ORCID: https://orcid.org/0000-0002-1125-3236, Seccia, Veronica, Kern, Robert C., Coste, André, Sousa, Ana R., Howarth, Peter H., Benson, Victoria S., Mayer, Bhabita, Yancey, Steve W., Chan, Robert and Gane, Simon B. (2022) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis. Allergy. ISSN 0105-4538

[img]
Preview
PDF (Allergy - 2022 - Fokkens - Mepolizumab for chronic rhinosinusitis with nasal polyps SYNAPSE in‐depth sinus surgery) - Published Version
Download (1MB) | Preview

Abstract

Background: Patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) often require repeat sinus surgery. Mepolizumab reduced the need for sinus surgery in the SYNAPSE trial; this analysis sought to provide a more in-depth assessment of surgery endpoints in SYNAPSE. Methods: SYNAPSE was a double-blind Phase III trial (NCT03085797) in adults with recurrent, refractory, severe, CRSwNP eligible for repeat sinus surgery despite standard of care treatments and previous surgery. Patients were randomized (1:1) to mepolizumab 100 mg subcutaneously or placebo, plus standard of care, every 4 weeks for 52 weeks. Time to first inclusion on a waiting list for sinus surgery and time to first actual sinus surgery (both up to week 52) were assessed; the latter endpoint was also analyzed post hoc according to time since last sinus surgery before study screening and baseline blood eosinophil count. Results: Among 407 patients (mepolizumab: 206; placebo: 201), mepolizumab versus placebo reduced the risk of being included on a waiting list for sinus surgery (week 52 Kaplan–Meier probability estimate [95% confidence interval]: 13.9% [9.8%, 19.5%] vs. 28.5% [22.7%, 35.4%]). Mepolizumab versus placebo reduced the risk of sinus surgery irrespective of time (<3 vs ≥3 years) since patients' last sinus surgery prior to study screening (hazard ratios [95% confidence intervals] 0.28 [0.09, 0.84] and 0.50 [0.26, 0.98], respectively) and baseline blood eosinophil count. Conclusions: Mepolizumab reduced the risk of further sinus surgery in patients with recurrent, refractory, severe CRSwNP, irrespective of the patient baseline characteristics assessed.

Item Type: Article
Uncontrolled Keywords: chronic rhinosinusitis with nasal polyps,mepolizumab,recurrence,refractory,sinonasal surgery,immunology and allergy,immunology ,/dk/atira/pure/subjectarea/asjc/2700/2723
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 25 Jul 2022 08:30
Last Modified: 09 Aug 2022 08:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/86835
DOI: 10.1111/all.15434

Actions (login required)

View Item View Item